摘要
目的:探讨18F-FDG SPECT/CT检查结合CA125检测在卵巢癌术后复发病例的早期诊断价值。方法:对43例卵巢癌术后病例同时进行18F-FDG SPECT/CT检查和CA125检测,怀疑复发的病例进行CT/MRI检查和临床随访,以进一步确诊。结果:43例病人中,18F-FDG SPECT/CT检查发现核素异常浓聚24例,经CT/MRI检查和临床资料证实为转移灶19例,阳性率和假阳性率分别为44.2%、11.6%,特异性为83.8%。本组病例CA125升高13例,证实为转移灶病例中CA125升高12例,阳性率和假阳性率分别为27.9%、2.3%,特异性为96.9%。结论:18F-FDG SPECT/CT检查和CA125检测是卵巢癌术后复发的可靠检查方法。
Objective:To investigate the diagnostic value of 18F-FDG SPECT/CT and CA125 in recurrent cases of ovarian cancer.Methods:Total of 43 ovarian cancer patients were examined by 18F-FDG SPECT/CT and CA125.All were followed-up.Results:There were 24 abnormal cases by 18F-FDG SPECT/CT and there were 19 cases confirmed metastases by clinical follow-up.The positive,false-positive rate and specificity were 44.2%,11.6%,and 83.8%.There were 13 abnormal cases of CA125 and there were 12 cases confirmed by clinical follow-up.The positive,false-positive rate and specificity were 27.9%,2.3%,and 96.9%.Conclusion:Detection of 18F-FDG SPECT/CT and CA125 were good way for diagnosis of ovarian cancer recurrence.
出处
《现代肿瘤医学》
CAS
2013年第6期1319-1321,共3页
Journal of Modern Oncology